Heather Raymon, Ph.D.
Vice President, Early Development
Heather Raymon, Ph.D., has 25 years of biotech and biopharma industry experience. Prior to Artiva, Dr. Raymon was Executive Director, Early Development Program Leadership at Celgene/Bristol Myers Squibb, where she was leading multiple clinical-stage programs in immuno-oncology and neuroscience. Prior to that, Dr. Raymon was Sr. Director and Head of Pharmacology at Celgene, where she built a department that was responsible for developing pharmacology data packages in support of regulatory filings in oncology and inflammation/immunology. Dr. Raymon started her biotech career at Signal Pharmaceuticals working in neurobiology and cellular and molecular pharmacology before the company was acquired by Celgene. Dr. Raymon received her B.S. in biology from SUNY Albany, a Ph.D. in pharmacology and toxicology at UC Irvine, and was a postdoctoral fellow at Salk Institute for Biological Studies and UC San Diego.